JP2025508502A5 - - Google Patents

Info

Publication number
JP2025508502A5
JP2025508502A5 JP2024551542A JP2024551542A JP2025508502A5 JP 2025508502 A5 JP2025508502 A5 JP 2025508502A5 JP 2024551542 A JP2024551542 A JP 2024551542A JP 2024551542 A JP2024551542 A JP 2024551542A JP 2025508502 A5 JP2025508502 A5 JP 2025508502A5
Authority
JP
Japan
Prior art keywords
dapanstril
patient
pharmaceutical composition
breast cancer
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063452 external-priority patent/WO2023168247A1/en
Publication of JP2025508502A publication Critical patent/JP2025508502A/ja
Publication of JP2025508502A5 publication Critical patent/JP2025508502A5/ja
Pending legal-status Critical Current

Links

JP2024551542A 2022-03-02 2023-03-01 潜在的不確定クローン性造血の固形癌患者の治療方法 Pending JP2025508502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263268793P 2022-03-02 2022-03-02
US63/268,793 2022-03-02
PCT/US2023/063452 WO2023168247A1 (en) 2022-03-02 2023-03-01 Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential

Publications (2)

Publication Number Publication Date
JP2025508502A JP2025508502A (ja) 2025-03-26
JP2025508502A5 true JP2025508502A5 (https=) 2026-03-11

Family

ID=87884332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551542A Pending JP2025508502A (ja) 2022-03-02 2023-03-01 潜在的不確定クローン性造血の固形癌患者の治療方法

Country Status (5)

Country Link
US (1) US20240417812A1 (https=)
EP (1) EP4487122A4 (https=)
JP (1) JP2025508502A (https=)
CN (1) CN119744351A (https=)
WO (1) WO2023168247A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121565B2 (en) * 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
EP4041924A1 (en) * 2019-10-08 2022-08-17 Illumina, Inc. Fragment size characterization of cell-free dna mutations from clonal hematopoiesis
EP4045009A4 (en) * 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER

Similar Documents

Publication Publication Date Title
Hu et al. Combined radiation therapy and immune checkpoint blockade therapy for breast cancer
Mehta et al. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood–brain barrier
JP2020158507A6 (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
HUE029255T2 (en) Duocarmycin adcs showing improved in vivo antitumor activity
JP2021510697A5 (https=)
JP2009539870A5 (https=)
Lindberg et al. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer
Bartsch et al. Optimal management of brain metastases from breast cancer: issues and considerations
Kerbel Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs
Yuan et al. Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
Demiray et al. Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report
Girda et al. Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer
JP2023505222A5 (https=)
Raucci et al. Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
Akil et al. Targeted radionuclide therapy decreases melanoma lung invasion by modifying epithelial-mesenchymal transition-like mechanisms
JP2025508502A5 (https=)
Özyurt et al. Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer
Klaas et al. Advanced breast cancer metastasized in the brain: treatment standards and innovations
Leyland-Jones et al. Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications
Song et al. Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer
Zalatnai Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma
Francini et al. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer
He et al. Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review
Barathidasan et al. Upregulated Myc expression in N-methyl nitrosourea (MNU)-induced rat mammary tumours
CN105497900A (zh) 一种抗未分化甲状腺癌耐药靶点及其应用